Argentina’s Active Pharmaceutical Ingredient (API) market has been undergoing significant evolution, positioning the country as a major player in the Latin American pharmaceutical industry. APIs, the critical components responsible for the therapeutic effects in drugs, are used to treat a wide range of medical conditions, from common ailments to complex, chronic diseases like diabetes, cardiovascular disorders, and cancer. These ingredients are produced through chemical synthesis or biologically derived processes, depending on the nature of the drug. In Argentina, the API market has seen substantial growth due to an increasing demand for both generic and biologic medicines, driven by the nation’s growing healthcare needs. With a population that is aging and facing rising incidences of chronic diseases, the demand for cost-effective and accessible pharmaceutical solutions is on the rise. The country’s pharmaceutical sector is also benefiting from innovations in biotechnology, which have led to a surge in the production of biologic APIs like monoclonal antibodies and vaccines. The Argentine government plays an essential role in this development by implementing policies that support the growth of the local pharmaceutical industry, including regulatory frameworks and incentives for domestic production. Argentina’s regulatory body, the National Administration of Drugs, Foods, and Medical Devices (ANMAT), ensures that APIs meet stringent quality standards, aligning with international guidelines to guarantee the safety and efficacy of pharmaceutical products. While the market continues to expand, it faces several challenges. Economic instability, including inflation and currency fluctuations, can increase production costs, limiting the competitiveness of local manufacturers. Access to high-quality raw materials is another challenge, with supply chains sometimes disrupted due to global trade conditions. Despite these obstacles, the Argentine pharmaceutical industry is thriving, with an increasing focus on research and development to innovate and meet both domestic and international demand. The growth of biologics and biosimilars presents a unique opportunity for the API market, as these products often require specialized manufacturing processes. The market is further buoyed by a shift towards generic drugs as many patented medications lose their exclusivity. The country’s pharmaceutical sector, supported by favorable government policies, continues to evolve, attracting foreign investment and fostering technological advancements, enabling Argentina to remain competitive within the broader Latin American and global pharmaceutical landscape.

According to the research report, "Argentina Active Pharmaceutical Ingredient Market Overview, 2030," published by Bonafide Research, the Argentina active pharmaceutical ingredient market is expected to reach a market size of more than USD 3.04 Billion by 2030. The market is experiencing steady growth, driven by an increasing demand for pharmaceuticals to treat chronic diseases such as diabetes, cardiovascular conditions, and cancer. The overall growth rate for the API market in Argentina is expected to continue at a strong pace, with a compound annual growth rate (CAGR) of approximately 5-6% over the next several years. This growth is fueled by the expanding healthcare needs of the aging population, increasing healthcare access, and a rising shift toward generic drugs. The demand for biologics and biosimilars is becoming more prominent, which has significantly contributed to the market expansion. At the country level, Argentina remains one of the largest pharmaceutical markets in Latin America, with a strong focus on improving local production to meet both domestic and global demand. The government has implemented several policies aimed at promoting local pharmaceutical manufacturing, including incentives for investment in production facilities and research and development. Key players in the Argentine API market include EMS Pharma, Aché Laboratórios, and Hypera Pharma, which are expanding their production capabilities to meet growing demand. Recent entrants include smaller, innovative firms focused on the biologics sector, adding further competition and capacity to the market. Between 2021 and 2024, significant developments in the market include regulatory updates that align with international standards to facilitate the export of Argentine APIs, as well as an increased emphasis on biotechnology for the development of biologic APIs. In terms of trade, Argentina's API market is well-integrated with global supply chains, with a focus on exporting to Latin America, Europe, and select markets in Asia. The country’s production capabilities have been bolstered by local access to raw materials, although there have been occasional disruptions in supply chains, particularly during the COVID-19 pandemic. The impact of COVID-19 was significant, with supply chains disrupted globally, leading to delays in API production and distribution. However, the market is gradually recovering, with improved manufacturing infrastructure and governmental support for the pharmaceutical sector. Looking ahead, the market is expected to grow significantly, driven by increased demand for generic medicines, government incentives for local production, and innovations in biologics.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


In Argentina, the Active Pharmaceutical Ingredients (API) market is predominantly driven by synthetic APIs, which are essential for the country’s pharmaceutical production. Synthetic APIs are favored for their cost-effectiveness and are widely used in the formulation of medicines that treat a variety of common ailments, such as infections, hypertension, diabetes, and pain management. With Argentina facing economic constraints and a large proportion of the population relying on public healthcare, synthetic APIs play a critical role in ensuring that essential medications remain affordable and accessible to a broad demographic. These APIs are particularly important in the context of generic medicines, which are crucial for making healthcare more accessible. The widespread adoption of synthetic APIs ensures that many basic healthcare needs are met, making them a backbone of the Argentine pharmaceutical industry. However, the biotech API sector is gradually gaining ground as well, especially in the treatment of complex and chronic diseases. Biotech APIs, which are derived from living organisms using advanced biotechnological techniques, are used in the production of biologics such as monoclonal antibodies, vaccines, and gene therapies. These biologics are becoming increasingly important in Argentina’s healthcare landscape due to their ability to treat conditions that traditional small-molecule drugs cannot address as effectively, such as certain types of cancer, autoimmune diseases, and rare genetic disorders. While the production of biotech APIs is more costly compared to synthetic APIs, their growing role in the treatment of complex diseases and the rising demand for advanced therapies are driving their adoption. Argentina’s healthcare system is slowly shifting toward these innovative biologics, especially as the population ages and the prevalence of chronic diseases increases. The combination of synthetic APIs for everyday healthcare and biotech APIs for specialized treatments is expected to shape the future of the Argentine API market, with biotech APIs likely to see increased adoption as the demand for targeted, advanced therapies continues to rise.

The Active Pharmaceutical Ingredients (API) market in Argentina is shaped by a combination of domestic production and imports, with a significant reliance on both captive and merchant manufacturing models. Major pharmaceutical companies in Argentina, such as Laboratorios Bagó and Roemmers, have increasingly focused on captive manufacturing to secure their supply chains and maintain control over the production of APIs, especially as global disruptions have highlighted the vulnerabilities of relying on imports. However, merchant manufacturing also plays a crucial role, with Argentina importing a large portion of its APIs from countries like India and China, where production costs are lower. This is particularly true in the generic drug sector, which is vital for Argentina’s public healthcare system and contributes to affordable access to medicines. In terms of API types, the Argentine market is dominated by generic APIs, driven by the country’s emphasis on cost-effective healthcare and the growing demand for affordable alternatives to branded drugs. While branded/innovative APIs are used for more complex treatments in areas like oncology, diabetes, and cardiovascular diseases, they remain less accessible due to their high cost. Generic APIs, on the other hand, help address the healthcare needs of a larger portion of the population. When considering drug types, prescription drugs make up the largest share of the market in Argentina, driven by the prevalence of chronic diseases such as hypertension, diabetes, and cancer, along with the country’s aging population. The growing demand for these drugs makes the availability of generic APIs critical. The over-the-counter (OTC) drug market is expanding in Argentina, with consumers increasingly turning to OTC medications for common ailments like pain relief, cold and flu symptoms, and digestive issues. This shift toward self-medication and preventative care has spurred demand for OTC drugs, contributing to the overall growth of the API market in Argentina, where the focus is on both increasing local production and maintaining affordable access to both prescription and OTC medications.

In Argentina, the Active Pharmaceutical Ingredients (API) market is integral to the country's healthcare system, addressing a broad range of medical conditions that affect its population. One of the dominant sectors within the API market is cardiovascular diseases. With a high prevalence of heart conditions such as hypertension, ischemic heart disease, arrhythmias, and strokes, cardiovascular health is a significant concern in Argentina. The demand for APIs in this area is driven by the need for medications to manage these chronic and life-threatening conditions, particularly as the country grapples with lifestyle-related risk factors such as high-fat diets and low physical activity. Moving to the oncology sector, cancer has emerged as one of the fastest-growing health concerns in Argentina. The rising incidence of cancers such as breast, prostate, lung, and colorectal cancer has resulted in a substantial demand for APIs used in the development of chemotherapy drugs, immunotherapy, and targeted therapies. These therapies are crucial for providing better outcomes for patients, making oncology a critical area of focus within the Argentine pharmaceutical market. Neurological disorders represent another growing segment, influenced by an aging population and increasing awareness of mental health issues. Conditions like Alzheimer's disease, Parkinson’s disease, multiple sclerosis, and epilepsy are on the rise, while mental health disorders, including depression, anxiety, and schizophrenia, contribute significantly to the country's healthcare burden. The rising demand for treatment options has led to an increased need for APIs used in psychiatric medications, neuroprotective agents, and treatments for cognitive decline. The growing burden of metabolic disorders is also notable in Argentina, with high rates of type 2 diabetes, obesity, and hyperthyroidism. These conditions are often linked to urbanization, dietary patterns, and sedentary lifestyles, and they are driving the demand for APIs in diabetes management, weight-loss drugs, and thyroid treatments. In Argentina, anti-infective drugs are particularly relevant due to the prevalence of infectious diseases such as tuberculosis, hepatitis, dengue, and antibiotic-resistant infections. The country continues to invest in efforts to curb the spread of these diseases, creating a strong demand for APIs used in antibiotics, antivirals, and antifungals. Respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pneumonia, are also common, exacerbated by environmental factors like pollution, smoking, and respiratory infections. The need for APIs to support the development of respiratory medications, such as bronchodilators and corticosteroids, remains high. Gastrointestinal issues like irritable bowel syndrome (IBS), ulcers, and gastritis contribute to the growing demand for APIs in digestive health treatments.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Manmayi Raval

Manmayi Raval

Research Consultant



The difference between Branded/Innovative APIs and Generic APIs fundamentally lies in their function in promoting pharmaceutical innovation and accessibility. Branded/Innovative APIs serve as the foundation for groundbreaking drug development, representing significant research and development (RandD) endeavors. These APIs are usually protected by patents and are linked with original medications that fulfill unmet medical requirements or present new therapeutic strategies. The key motivator here is innovation, as pharmaceutical firms allocate billions towards RandD, clinical trials, and regulatory adherence to successfully launch these APIs. As a result, they are set at higher prices to recoup the considerable investment and to support future innovation. Conversely, Generic APIs are intended to mimic the therapeutic benefits of branded medications once their patents have lapsed. These APIs form the basis of generic drugs, which provide equivalent quality, efficacy, and safety as their branded equivalents but at a markedly lower price. The main reason for their significance is affordability and accessibility. Generic APIs lower healthcare expenses and enhance access to life-saving treatments, especially in low- and middle-income nations. Producers of generic APIs do not incur the substantial RandD costs related to the creation of new medications; instead, they concentrate on reverse-engineering the formula and confirming bioequivalence. This financial benefit enables generic APIs to play a crucial role in global healthcare by alleviating the economic burden of illnesses and ensuring essential medicines are available to a larger population. While branded/innovative APIs propel pharmaceutical innovation by launching advanced therapies, generic APIs are vital in making healthcare accessible. Their cost-effectiveness influences the lives of millions, rendering healthcare systems more sustainable and fairer. This dynamic equilibrium between innovation and accessibility secures the essentiality of both types of APIs in the pharmaceutical sector's objective of enhancing global health outcomes.

The essential difference between Prescription Drugs and Over-the-Counter (OTC) Drugs regarding active pharmaceutical ingredients (APIs) is in the extent of medical oversight needed for their usage. Prescription drugs include APIs that generally address more complicated, chronic, or potentially life-threatening conditions, requiring supervision by healthcare professionals. These medications are designed for personalized patient care and need a doctor's approval because of the risk of serious side effects, interactions, or misuse if not administered properly. The APIs found in prescription drugs often represent leading pharmaceutical research, targeting specific therapeutic needs and providing high effectiveness for exact medical requirements. Consequently, their use is closely regulated, assuring safety and efficacy under professional oversight. Conversely, OTC drugs feature APIs that are designed for self-treatment of minor or common issues, such as headaches, colds, or mild allergies. These medications are regarded as safe and effective when used as directed, without needing involvement from a healthcare provider. The most pivotal reason for their significance is empowering consumers with accessible and convenient healthcare options. OTC drugs help alleviate the strain on healthcare systems by allowing individuals to manage minor health concerns on their own, which frees up resources for more urgent medical situations. Their APIs are generally well-recognized and validated for a wide safety margin, with clear labeling and dosage guidelines minimizing the potential for misuse. While prescription drugs depend on advanced APIs to tackle serious health issues under medical supervision, OTC drugs are propelled by APIs that encourage self-care and availability. Together, they form a harmonious healthcare system, catering to both critical health requirements and everyday health matters. By equipping consumers with trustworthy OTC alternatives, APIs in these medications significantly improve public health outcomes, promoting greater independence in handling routine healthcare needs.

Considered in this report
• Historic year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Manmayi Raval


Aspects covered in this report
• Active Pharmaceutical Ingredients market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Based on a synthesis of Active Pharmaceutical Ingredients in the report
• Synthetic API
• Biotech API

Based on the drug type of Active Pharmaceutical Ingredients in the report
• Branded API
• Generic API

Based on the type of manufacture of Active Pharmaceutical Ingredients in the report
• Captive API
• Merchant API

By Therapeutic Application Type in the report
• Communicable Diseases
• Oncology
• Diabetes
• Cardiovascular Disease
• Pain management
• Respiratory Diseases
• Other Therapeutic Applications

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to Active Pharmaceutical Ingredients industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

Table of Contents

  • 1. Executive Summary
  • 2. Market Structure
  • 2.1. Market Considerate
  • 2.2. Assumptions
  • 2.3. Limitations
  • 2.4. Abbreviations
  • 2.5. Sources
  • 2.6. Definitions
  • 2.7. Geography
  • 3. Research Methodology
  • 3.1. Secondary Research
  • 3.2. Primary Data Collection
  • 3.3. Market Formation & Validation
  • 3.4. Report Writing, Quality Check & Delivery
  • 4. Argentina Macro Economic Indicators
  • 5. Market Dynamics
  • 5.1. Market Drivers & Opportunities
  • 5.2. Market Restraints & Challenges
  • 5.3. Market Trends
  • 5.3.1. XXXX
  • 5.3.2. XXXX
  • 5.3.3. XXXX
  • 5.3.4. XXXX
  • 5.3.5. XXXX
  • 5.4. Covid-19 Effect
  • 5.5. Supply chain Analysis
  • 5.6. Policy & Regulatory Framework
  • 5.7. Industry Experts Views
  • 6. Argentina Active Pharmaceutical Ingredients Market Overview
  • 6.1. Market Size By Value
  • 6.2. Market Size and Forecast, By Application
  • 6.3. Market Size and Forecast, By Synthesis Type
  • 6.4. Market Size and Forecast, By Type of Manufacture
  • 6.5. Market Size and Forecast, By Region
  • 7. Argentina Active Pharmaceutical Ingredients Market Segmentations
  • 7.1. Argentina Active Pharmaceutical Ingredients Market, By Application
  • 7.1.1. Argentina Active Pharmaceutical Ingredients Market Size, By Anti-infective, 2019-2030
  • 7.1.2. Argentina Active Pharmaceutical Ingredients Market Size, By Cardiovascular, 2019-2030
  • 7.1.3. Argentina Active Pharmaceutical Ingredients Market Size, By Neurological, 2019-2030
  • 7.1.4. Argentina Active Pharmaceutical Ingredients Market Size, By Metabolic Disorder, 2019-2030
  • 7.1.5. Argentina Active Pharmaceutical Ingredients Market Size, By Oncology, 2019-2030
  • 7.1.6. Argentina Active Pharmaceutical Ingredients Market Size, By Others, 2019-2030
  • 7.2. Argentina Active Pharmaceutical Ingredients Market, By Synthesis Type
  • 7.2.1. Argentina Active Pharmaceutical Ingredients Market Size, By Synthetic API, 2019-2030
  • 7.2.2. Argentina Active Pharmaceutical Ingredients Market Size, By Biotech API, 2019-2030
  • 7.3. Argentina Active Pharmaceutical Ingredients Market, By Type of Manufacture
  • 7.3.1. Argentina Active Pharmaceutical Ingredients Market Size, By Captive, 2019-2030
  • 7.3.2. Argentina Active Pharmaceutical Ingredients Market Size, By Merchant, 2019-2030
  • 7.4. Argentina Active Pharmaceutical Ingredients Market, By Region
  • 7.4.1. Argentina Active Pharmaceutical Ingredients Market Size, By North, 2019-2030
  • 7.4.2. Argentina Active Pharmaceutical Ingredients Market Size, By East, 2019-2030
  • 7.4.3. Argentina Active Pharmaceutical Ingredients Market Size, By West, 2019-2030
  • 7.4.4. Argentina Active Pharmaceutical Ingredients Market Size, By South, 2019-2030
  • 8. Argentina Active Pharmaceutical Ingredients Market Opportunity Assessment
  • 8.1. By Application, 2025 to 2030
  • 8.2. By Synthesis Type, 2025 to 2030
  • 8.3. By Type of Manufacture, 2025 to 2030
  • 8.4. By Region, 2025 to 2030
  • 9. Competitive Landscape
  • 9.1. Porter's Five Forces
  • 9.2. Company Profile
  • 9.2.1. Company 1
  • 9.2.1.1. Company Snapshot
  • 9.2.1.2. Company Overview
  • 9.2.1.3. Financial Highlights
  • 9.2.1.4. Geographic Insights
  • 9.2.1.5. Business Segment & Performance
  • 9.2.1.6. Product Portfolio
  • 9.2.1.7. Key Executives
  • 9.2.1.8. Strategic Moves & Developments
  • 9.2.2. Company 2
  • 9.2.3. Company 3
  • 9.2.4. Company 4
  • 9.2.5. Company 5
  • 9.2.6. Company 6
  • 9.2.7. Company 7
  • 9.2.8. Company 8
  • 10. Strategic Recommendations
  • 11. Disclaimer

Table 1: Influencing Factors for Active Pharmaceutical Ingredients Market, 2024
Table 2: Argentina Active Pharmaceutical Ingredients Market Size and Forecast, By Application (2019 to 2030F) (In USD Million)
Table 3: Argentina Active Pharmaceutical Ingredients Market Size and Forecast, By Synthesis Type (2019 to 2030F) (In USD Million)
Table 4: Argentina Active Pharmaceutical Ingredients Market Size and Forecast, By Type of Manufacture (2019 to 2030F) (In USD Million)
Table 5: Argentina Active Pharmaceutical Ingredients Market Size and Forecast, By Region (2019 to 2030F) (In USD Million)
Table 6: Argentina Active Pharmaceutical Ingredients Market Size of Anti-infective (2019 to 2030) in USD Million
Table 7: Argentina Active Pharmaceutical Ingredients Market Size of Cardiovascular (2019 to 2030) in USD Million
Table 8: Argentina Active Pharmaceutical Ingredients Market Size of Neurological (2019 to 2030) in USD Million
Table 9: Argentina Active Pharmaceutical Ingredients Market Size of Metabolic Disorder (2019 to 2030) in USD Million
Table 10: Argentina Active Pharmaceutical Ingredients Market Size of Oncology (2019 to 2030) in USD Million
Table 11: Argentina Active Pharmaceutical Ingredients Market Size of Others (2019 to 2030) in USD Million
Table 12: Argentina Active Pharmaceutical Ingredients Market Size of Synthetic API (2019 to 2030) in USD Million
Table 13: Argentina Active Pharmaceutical Ingredients Market Size of Biotech API (2019 to 2030) in USD Million
Table 14: Argentina Active Pharmaceutical Ingredients Market Size of Captive (2019 to 2030) in USD Million
Table 15: Argentina Active Pharmaceutical Ingredients Market Size of Merchant (2019 to 2030) in USD Million
Table 16: Argentina Active Pharmaceutical Ingredients Market Size of North (2019 to 2030) in USD Million
Table 17: Argentina Active Pharmaceutical Ingredients Market Size of East (2019 to 2030) in USD Million
Table 18: Argentina Active Pharmaceutical Ingredients Market Size of West (2019 to 2030) in USD Million
Table 19: Argentina Active Pharmaceutical Ingredients Market Size of South (2019 to 2030) in USD Million

Figure 1: Argentina Active Pharmaceutical Ingredients Market Size By Value (2019, 2024 & 2030F) (in USD Million)
Figure 2: Market Attractiveness Index, By Application
Figure 3: Market Attractiveness Index, By Synthesis Type
Figure 4: Market Attractiveness Index, By Type of Manufacture
Figure 5: Market Attractiveness Index, By Region
Figure 6: Porter's Five Forces of Argentina Active Pharmaceutical Ingredients Market
Logo

Argentina Active Pharmaceutical Ingredient (API) Market Overview, 2030

Contact usWe are friendly and approachable, give us a call.